local_hospital

Ujpesti Egeszsegugyi Nonprofit Kft.

Address
Gorgey Artur Ut 30, 1046 Budapest, Hungary

Nutritional and Metabolic Diseases

At Ujpesti Egeszsegugyi Nonprofit Kft. in Budapest, clinical research in Nutritional and Metabolic Diseases focuses on obesity and overweight, with studies aimed at improving long-term health outcomes and reducing serious complications linked to excess weight.

  • Testing new treatment approaches for weight management
  • Evaluating whether therapies can lower heart-related and kidney risks
  • Studying the impact of treatment on morbidity and mortality

This area reflects a strong interest in therapies that go beyond weight loss alone and look at broader disease prevention and overall health protection.

Otorhinolaryngologic Diseases

The site is also active in Otorhinolaryngologic Diseases, with trials centered on chronic rhinosinusitis with nasal polyps and related severe forms, including patients who also have asthma. These studies aim to ease nasal blockage, reduce polyp burden, and improve day-to-day breathing and comfort.

  • Assessing treatments for nasal polyp reduction
  • Improving nasal congestion and sinus symptom control
  • Exploring patient experience and treatment satisfaction

Research in this field combines symptom relief with a closer look at how people experience their condition during treatment.

Respiratory Tract Diseases

In Respiratory Tract Diseases, the clinical trials at this hospital/clinic site examine chronic rhinosinusitis with nasal polyps as a condition that affects breathing, nasal function, and overall respiratory well-being. The goal is to test new therapies that may better control inflammation and improve patient outcomes.

  • Evaluating biologic therapies for severe nasal and sinus disease
  • Measuring changes in congestion and polyp size
  • Supporting better symptom control in difficult-to-treat respiratory conditions

With a small but focused research portfolio, the Department of Ujpesti Egeszsegugyi Szolgaltato Nonprofit Kft. contributes to studies that aim to advance care for persistent upper airway disease.

Site Overview

assignment
5
connected trials
corporate_fare
3
sponsors
science
4
IMPs

Activity Indicator

Last 6 months

1
Trials started
0% vs previous period.
1
Trials started 6–12 months ago
5
Total trials linked
Active
trending_flatStable0%
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status
lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
3
Sponsors (total)
3
Active sponsors
2

Sponsor Network

Top 2 by active trials.

lock +1 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +1 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 332 other sites in Hungary

description
Trial volume
5
Outperforms 58% of sites
public
Therapeutic diversity
3areas
Outperforms 67% of sites
groups
Sponsor diversity
3sponsors
Outperforms 55% of sites

Therapeutic Area Benchmark — Hungary

Select a therapeutic area to compare against other sites in Hungary.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Hungary

Market Share

Country: Hungary

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Ujpesti Egeszsegugyi Nonprofit Kft.

lock Showing 1 of 5 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
Effect of Orforglipron on Major Adverse Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney DiseaseEli Lilly & Co.Phase IIIRecruitingMay 2026

IMP list

lock Showing 1 of 4 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Itepekimab2Unknown2025-05-202026-06-23

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.